DSS, Inc. announced a public offering of Common Stock to support general corporate needs, managed by Aegis Capital Corp.
Quiver AI Summary
DSS, Inc., a multinational company engaged in packaging, wealth management, and biohealth innovation, announced on February 3, 2026, the commencement of a public offering of its Common Stock to raise funds for general corporate and working capital needs. The offering, which is subject to market conditions, will be managed by Aegis Capital Corp. and is being conducted under an effective registration statement previously filed with the SEC. DSS's Common Stock trades on the NYSE American LLC under the symbol "DSS." A final prospectus supplement detailing the offering terms will be available on the SEC's website and through Aegis Capital Corp. The company emphasizes that this announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities.
Potential Positives
- The commencement of a public offering indicates DSS, Inc. is seeking to raise funds, which can bolster its working capital and support general corporate needs.
- The involvement of Aegis Capital Corp. as the sole book-running manager suggests that the offering is being backed by a reputable financial institution, which may increase investor confidence.
- The effective shelf registration statement allows for flexibility in raising capital in alignment with market conditions, providing DSS, Inc. with strategic options.
Potential Negatives
- The announcement of a public offering may indicate a need for additional capital, which could raise concerns about the company's current financial health.
- The lack of assurance on the completion of the offering or its terms suggests uncertainty that could negatively impact investor confidence.
- Significant reliance on forward-looking statements may highlight potential vulnerabilities in the company's future performance, which could deter cautious investors.
FAQ
What is the purpose of DSS, Inc.'s public offering?
The net proceeds will be used for general corporate and working capital needs.
Who is managing the DSS, Inc. offering?
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
Where can I find the final prospectus for the DSS offering?
The final prospectus will be filed with the SEC and available on their website at www.sec.gov.
What does DSS, Inc. do?
DSS, Inc. operates across multiple industries including health and wellness, packaging, and blockchain.
When was the effective registration statement for the offering filed?
The effective shelf registration statement was filed on October 31, 2024.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DSS Insider Trading Activity
$DSS insiders have traded $DSS stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $DSS stock by insiders over the last 6 months:
- HENG FAI AMBROSE CHAN sold 130,679 shares for an estimated $176,089
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DSS Hedge Fund Activity
We have seen 6 institutional investors add shares of $DSS stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 43,744 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $59,054
- TWO SIGMA SECURITIES, LLC removed 10,200 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $13,770
- RENAISSANCE TECHNOLOGIES LLC added 4,000 shares (+14.6%) to their portfolio in Q3 2025, for an estimated $5,400
- GEODE CAPITAL MANAGEMENT, LLC added 3,645 shares (+19.0%) to their portfolio in Q3 2025, for an estimated $4,920
- CITIGROUP INC added 2,937 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,964
- TOWER RESEARCH CAPITAL LLC (TRC) removed 1,890 shares (-42.6%) from their portfolio in Q3 2025, for an estimated $2,551
- UBS GROUP AG added 372 shares (+inf%) to their portfolio in Q4 2025, for an estimated $345
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that it has commenced a public offering to offer and sell shares of its Common Stock.
All of the shares of Common Stock are being offered by the Company (the “Offering”).
The Company intends to use the net proceeds from the Offering for general corporate and working capital needs. The Company’s Common Stock is trading on the NYSE American LLC under the symbol “DSS”. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
Aegis Capital Corp. is acting as the sole book-running manager for the offering on a firm commitment basis.
The offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-281974) previously filed with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024, and declared effective by the SEC on November 5, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov . Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at [email protected], or by telephone at +1 (212) 813-1010.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About DSS, Inc.
DSS, Inc. is a multinational company operating across multiple business lines including health and wellness, packaging, real estate, and securities and blockchain. The Company operates a business model based on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings. For more information, visit www.dssworld.com.
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
For investor and media inquiries or additional information, please contact:
Investor Contact:
DSS, Inc.
Investor Relations
[email protected]
+1 (585) 565-2422
